Loss-of-Function Mutations inAPOC3,Triglyceric

New England Journal of Medicine
371, 22-31
DOI: 10.1056/nejmoa1307095

Citation Report

#	Article	IF	Citations
1	Genetics of coronary artery disease â€“ A clinician's perspective. Indian Heart Journal, 2014, 66, 663-671.	0.2	12
2	Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins. Nutrition and Metabolism, 2014, 11, 56.	1.3	7
3	Using genetically isolated populations to understand the genomic basis of disease. Genome Medicine, 2014, 6, 83.	3.6	26
4	APOC3 mutations lower CVD risk. Nature Reviews Cardiology, 2014, 11, 496-496.	6.1	6
5	Resurgence of targets and compounds to treat dyslipidaemia. Nature Reviews Cardiology, 2014, 11, 629-631.	6.1	7
6	Targeting APOC3 in the Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2014, 371, 2200-2206.	13.9	376
7	Evolving targets for lipidâ€modifying therapy. EMBO Molecular Medicine, 2014, 6, 1215-1230.	3.3	11
8	Knowns and unknowns for psychophysiological endophenotypes: Integration and response to commentaries. Psychophysiology, 2014, 51, 1339-1347.	1.2	51
9	Glucagon-Like Peptide-2 Regulates Release of Chylomicrons From the Intestine. Gastroenterology, 2014, 147, 1275-1284.e4.	0.6	73
10	Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2014, 64, 2525-2540.	1.2	192
11	Triglyceride and HDL. Current Opinion in Lipidology, 2014, 25, 404-405.	1.2	0
12	Inhibition of ApoCIII. Current Opinion in Lipidology, 2014, 25, 418-422.	1.2	22
13	HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack. Global Cardiology Science & Practice, 2014, 2014, 37.	0.3	3
14	APOC3: Triglycerides do matter. Global Cardiology Science & Practice, 2014, 2014, 38.	0.3	5
15	Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease. New England Journal of Medicine, 2014, 371, 2072-2082.	13.9	386
16	Dyslipidaemia in perspective. Lancet, The, 2014, 384, 566-568.	6.3	4
17	Triglycerides and cardiovascular disease. Lancet, The, 2014, 384, 626-635.	6.3	1,005
18	HDL and cognition in neurodegenerative disorders. Neurobiology of Disease, 2014, 72, 22-36.	2.1	118

#	Article	IF	Citations
19	Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in Lipid Research, 2014, 56, 47-66.	5.3	128
20	Diabetic dyslipidemia. Metabolism: Clinical and Experimental, 2014, 63, 1469-1479.	1.5	344
21	APOC3, Coronary Disease, and Complexities of Mendelian Randomization. Cell Metabolism, 2014, 20, 387-389.	7.2	34
22	Unraveling New Therapeutic Targets of Coronary Artery Disease by Genetic Approaches. Circulation Journal, 2014, 79, 8-14.	0.7	6
23	Lipid-modifying Therapy: The Clinicianâ€™s Perspective. Clinical Therapeutics, 2015, 37, 2712-2715.	1.1	0
24	Atherosclerosis: Is a cure in sight?. Journal of Clinical Lipidology, 2015, 9, S1-S4.	0.6	2
25	Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. Journal of Internal Medicine, 2015, 278, 433-446.	2.7	30
26	NHLBI Strategic Visioning: setting an agenda together for the NHLBI of 2025. Blood, 2015, 125, 2733-2735.	0.6	1
27	Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia. Clinical Lipidology, 2015, 10, 191-203.	0.4	7
28	Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids in Health and Disease, 2015, 14, 98.	1.2	46
29	Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology, 2015, 26, 484-491.	1.2	35
30	Dysbetalipoproteinemia. Current Opinion in Lipidology, 2015, 26, 292-297.	1.2	25
31	National Heart, Lung, and Blood Institute Strategic Visioning: Setting an Agenda Together for the NHLBI of 2025. American Journal of Public Health, 2015, 105, e25-e28.	1.5	21
32	Association of the Lipoprotein Receptor SCARB1 Common Missense Variant rs4238001 with Incident Coronary Heart Disease. PLoS ONE, 2015, 10, e0125497.	1.1	26
33	The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. PLoS ONE, 2015, 10, e0144138.	1.1	35
34	Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel. European Heart Journal, 2015, 36, 1424-1427.	1.0	5
35	Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, e3-9.	1.1	61
36	Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl. Cardiology and Therapy, 2015, 4, 83-93.	1.1	17

#	Article	IF	Citations
37	Modulators of Hepatic Lipoprotein Metabolism Identified in a Search for Small-Molecule Inducers of Tribbles Pseudokinase 1 Expression. PLoS ONE, 2015, 10, e0120295.	1.1	25
38	Twenty-five years of statins: where do we go from here?. Clinical Lipidology, 2015, 10, 33-45.	0.4	2
39	Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia. Lipids in Health and Disease, 2015, 14, 27.	1.2	22
40	Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. Journal of the American College of Cardiology, 2015, 65, 2267-2275.	1.2	210
41	Mendel, Molecular Biology, and Apolipoprotein C-III: A Heady Combination. Metabolic Syndrome and Related Disorders, 2015, 13, 55-56.	0.5	0
42	The Remnants of Residual Riskâ^—. Journal of the American College of Cardiology, 2015, 65, 2276-2278.	1.2	19
43	Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. Atherosclerosis Supplements, 2015, 18, 109-111.	1.2	37
44	Lipoproteins and Cardiovascular Disease Risk. Contemporary Endocrinology, 2015, , 57-65.	0.3	0
45	Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia. DMM Disease Models and Mechanisms, 2015, 8, 989-98.	1.2	54
46	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2218-2224.	1.1	58
47	NHLBI Strategic Visioning: Setting an Agenda Together for the NHLBI of 2025. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 489-491.	2.5	8
48	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. Clinical Therapeutics, 2015, 37, 2732-2750.	1.1	7
49	Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 375-391.	1.8	42
50	GWAS as a Driver of Gene Discovery in Cardiometabolic Diseases. Trends in Endocrinology and Metabolism, 2015, 26, 722-732.	3.1	29
51	Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nature Communications, 2015, 6, 10206.	5.8	86
52	A Novel Apolipoprotein C-II Mimetic Peptide That Activates Lipoprotein Lipase and Decreases Serum Triglycerides in Apolipoprotein Eâ€"Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 227-235.	1.3	48
53	Hypertriglyceridemia in the Genomic Era: A New Paradigm. Endocrine Reviews, 2015, 36, 131-147.	8.9	118
54	Ï‰-3 carboxylic acids for hypertriglyceridemia. Expert Opinion on Pharmacotherapy, 2015, 16, 123-133.	0.9	8

#	Article	IF	Citations
56	Therapeutic genome editing: prospects and challenges. Nature Medicine, 2015, 21, 121-131.	15.2	1,042
57	Human genetics of HDL: Insight into particle metabolism and function. Progress in Lipid Research, 2015, 58, 14-25.	5.3	45
58	Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Human Molecular Genetics, 2015, 24, 2390-2400.	1.4	47
59	National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning. Journal of the American College of Cardiology, 2015, 65, 1130-1133.	1.2	12
60	Shared Genetic Aetiology of Coronary Artery Disease and Atherosclerotic Strokeâ€"2015. Current Atherosclerosis Reports, 2015, 17, 498.	2.0	8
61	Lipid Management. , 2015, , .		1
62	A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects. Journal of Proteome Research, 2015, 14, 2792-2806.	1.8	46
64	Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. New England Journal of Medicine, 2015, 373, 438-447.	13.9	445
65	Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis, 2015, 241, 641-648.	0.4	16
66	Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis. Biochemical and Biophysical Research Communications, 2015, 462, 420-425.	1.0	2
67	Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture: Figure 1. Diabetes, 2015, 64, 2689-2697.	0.3	17
68	Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1880-1888.	1.1	60
69	Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. Cardiovascular Research, 2015, 107, 579-589.	1.8	50
70	LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?. Current Cardiology Reports, 2015, 17, 610.	1.3	11
71	National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning. Circulation, 2015, 131, 1106-1109.	1.6	6
72	Analysis of loss-of-function variants and 20 risk factor phenotypes in 8,554 individuals identifies loci influencing chronic disease. Nature Genetics, 2015, 47, 640-642.	9.4	49
73	Personalized medicine in diabetes mellitus: current opportunities and future prospects. Annals of the New York Academy of Sciences, 2015, 1346, 45-56.	1.8	69
74	Statin treatment: can genetics sharpen the focus?. Lancet, The, 2015, 385, 2227-2229.	6.3	10

#	Article	IF	Citations
75	Developing Medicines That Mimic the Natural Successes of the Human Genome. Journal of the American College of Cardiology, 2015, 65, 1562-1566.	1.2	39
76	Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. Journal of Clinical Lipidology, 2015, 9, 360-367.	0.6	22
77	Rare variant association studies: considerations, challenges and opportunities. Genome Medicine, 2015, 7, 16.	3.6	176
78	Triglycerides on the rise: should we swap seats on the seesaw?. European Heart Journal, 2015, 36, 774-776.	1.0	71
79	New Insights into the Regulation of Chylomicron Production. Annual Review of Nutrition, 2015, 35, 265-294.	4.3	140
80	Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods, 2015, 81, 86-92.	1.9	42
81	Textbook of Personalized Medicine. , 2015, , .		27
82	A 3-day-old neonate with severe hypertriglyceridemia from novel mutations of the GPIHBP1 gene. Journal of Clinical Lipidology, 2015, 9, 265-270.	0.6	22
83	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€"Full Report. Journal of Clinical Lipidology, 2015, 9, 129-169.	0.6	632
84	Obesity and Ischemic Heart Disease. Circulation Research, 2015, 116, 570-571.	2.0	7
85	Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents. , 2015, , 589-611.		0
86	Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. Annual Review of Genomics and Human Genetics, 2015, 16, 327-350.	2.5	298
87	Next-generation gene discovery for variants of large impact on lipid traits. Current Opinion in Lipidology, 2015, 26, 114-119.	1.2	5
88	Therapy and clinical trials. Current Opinion in Lipidology, 2015, 26, 70-71.	1.2	0
89	PCSK9 inhibition to reduce cardiovascular disease risk. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 126-132.	1.2	24
90	Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities. Current Opinion in HIV and AIDS, 2015, 10, 116-122.	1.5	14
91	Recent developments in genome and exome-wide analyses of plasma lipids. Current Opinion in Lipidology, 2015, 26, 96-102.	1.2	24
92	HDL re-examined. Current Opinion in Lipidology, 2015, 26, 127-132.	1.2	35

#	Article	IF	Citations
93	Apolipoprotein C-III. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 119-125.	1.2	87
94	Translational Research Methods: Basics of Renal Molecular Biology. , 2015, , 1-22.		0
95	Human Genetics of Atherothrombotic Disease and its Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 741-747.	1.1	9
96	Apolipoprotein C-III: From Pathophysiology to Pharmacology. Trends in Pharmacological Sciences, 2015, 36, 675-687.	4.0	144
97	The Role of Omega-3 Fatty Acids in Dyslipidemias. , 2015, , 45-64.		1
98	Association of APOC3 ÂLoss-of-Function Mutations With PlasmaÂLipids and Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2015, 66, 2053-2055.	1.2	41
99	Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrology, 2015, 16, 130.	0.8	14
100	Protective alleles and modifier variants in human health and disease. Nature Reviews Genetics, 2015, 16, 689-701.	7.7	105
101	Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis, 2015, 242, 357-366.	0.4	144
102	Moderate Exercise Increases Affinity of Large Very Low-Density Lipoproteins for Hydrolysis by Lipoprotein Lipase. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2205-2213.	1.8	25
103	Tryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2821-2828.	1.4	4
104	Sexâ€Specific Parental Effects on Offspring Lipid Levels. Journal of the American Heart Association, 2015, 4, .	1.6	8
105	Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). Journal of Medicinal Chemistry, 2015, 58, 7173-7185.	2.9	61
106	The UK10K project identifies rare variants in health and disease. Nature, 2015, 526, 82-90.	13.7	1,014
107	Secondary hypertriglyceridemia in children and adolescents. Journal of Clinical Lipidology, 2015, 9, S29-S40.	0.6	27
108	A comprehensive 1000 Genomesâ€"based genome-wide association meta-analysis of coronary artery disease. Nature Genetics, 2015, 47, 1121-1130.	9.4	2,054
109	Insights into blood lipids from rare variant discovery. Current Opinion in Genetics and Development, 2015, 33, 25-31.	1.5	4
110	Infrequent TRIB3 coding variants and coronary artery disease in type 2 diabetes. Atherosclerosis, 2015, 242, 334-339.	0.4	11

#	Article	IF	Citations
112	The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis. Journal of Clinical Lipidology, 2015, 9, 498-510.	0.6	106
113	JCL roundtable: Apolipoproteins as causative elements in vascular disease. Journal of Clinical Lipidology, 2015, 9, 733-740.	0.6	6
114	Human knockout research: new horizons and opportunities. Trends in Genetics, 2015, 31, 108-115.	2.9	42
115	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015, 518, 102-106.	13.7	581
116	Implications of reverse cholesterol transport: Recent studies. Clinica Chimica Acta, 2015, 439, 154-161.	0.5	30
117	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. Current Medical Research and Opinion, 2015, 31, 435-438.	0.9	4
119	Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study. Clinical Medicine Insights: Cardiology, 2016, 10, CMC.S38123.	0.6	4
120	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
121	Common and Rare Variant Association Study for Plasma Lipids and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2016, 23, 241-256.	0.9	15
122	The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Reports, 2016, 49, 139-148.	1.1	57
123	Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases. , 2016, , 159-176.		0
124	Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. Cardiology, 2016, 135, 3-12.	0.6	11
125	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vascular Health and Risk Management, 2016, 12, 171.	1.0	166
126	Hypertriglyceridemia and Cardiovascular Diseases: Revisited. Korean Circulation Journal, 2016, 46, 135.	0.7	39
127	Zebrafish Models for Dyslipidemia and Atherosclerosis Research. Frontiers in Endocrinology, 2016, 7, 159.	1.5	28
128	Neuroendocrinological and Epigenetic Mechanisms Subserving Autonomic Imbalance and HPA Dysfunction in the Metabolic Syndrome. Frontiers in Neuroscience, 2016, 10, 142.	1.4	33
129	Lipids in Coronary Heart Disease. , 2016, , 67-80.		0
130	Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management. World Journal of Hepatology, 2016, 8, 827.	0.8	20

#	Article	IF	Citations
131	What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants?. Current Opinion in Lipidology, 2016, 27, 99-104.	1.2	4
132	Novel therapies for severe dyslipidemia originating from human genetics. Current Opinion in Lipidology, 2016, 27, 112-124.	1.2	18
133	Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say. International Journal of Clinical Practice, 2016, 70, 142-146.	0.8	0
134	Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?. Current Cardiology Reports, 2016, 18, 67.	1.3	74
135	A genome-wide study of lipid response to fenofibrate in Caucasians. Pharmacogenetics and Genomics, 2016, 26, 324-333.	0.7	12
136	Using human genetics to predict the effects and side-effects of drugs. Current Opinion in Lipidology, 2016, 27, 105-111.	1.2	10
137	Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism. Current Opinion in Lipidology, 2016, 27, 14-18.	1.2	10
138	Meta-analysis of 49â€…549 individuals imputed with the 1000 Genomes Project reveals an exonic damaging variant inANGPTL4determining fasting TG levels. Journal of Medical Genetics, 2016, 53, 441-449.	1.5	34
139	Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science, 2016, 354, .	6.0	464
140	Genetics: Implications for Prevention and Management of Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 2797-2818.	1.2	92
141	The impact of genomeâ€wide association studies onÂthe pathophysiology and therapy of cardiovascular disease. EMBO Molecular Medicine, 2016, 8, 688-701.	3.3	141
142	Variants inANGPTL4and the Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2303-2306.	13.9	18
143	Identification of Shared and Unique Serum Lipid Profiles in Diabetes Mellitus and Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	12
144	Genetics of Lipid and Lipoprotein Disorders and Traits. Current Genetic Medicine Reports, 2016, 4, 130-141.	1.9	61
145	Merging Electronic Health Record Data and Genomics for Cardiovascular Research. Circulation: Cardiovascular Genetics, 2016, 9, 193-202.	5.1	20
146	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology, 2016, 67, 2578-2589.	1.2	723
147	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Journal of Clinical Lipidology, 2016, 10, 472-489.	0.6	219
148	Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Current Cardiology Reports, 2016, 18, 65.	1.3	13

#	Article	IF	Citations
149	Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. Atherosclerosis, 2016, 250, 63-68.	0.4	11
150	Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease. American Journal of Cardiology, 2016, 118, 138-145.	0.7	134
151	KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. Medical Oncology, 2016, 33, 32.	1.2	25
152	Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Translational Research, 2016, 173, 30-57.	2.2	75
153	Coding Variation inANGPTL4,LPL,andSVEP1and the Risk of Coronary Disease. New England Journal of Medicine, 2016, 374, 1134-1144.	13.9	427
154	Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches. Expert Review of Cardiovascular Therapy, 2016, 14, 855-869.	0.6	37
155	JCL roundtable: Lessons from genetic variants altering lipoprotein metabolism. Journal of Clinical Lipidology, 2016, 10, 448-457.	0.6	1
156	Nutrigenomics, the Microbiome, and Gene-Environment Interactions: New Directions in Cardiovascular Disease Research, Prevention, and Treatment. Circulation: Cardiovascular Genetics, 2016, 9, 291-313.	5.1	99
157	Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genetics, 2016, 48, 634-639.	9.4	214
158	Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. American Journal of Cardiovascular Drugs, 2016, 16, 229-239.	1.0	46
159	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 2016, 5, .	1.6	121
160	GPIHBP1 and Plasma Triglyceride Metabolism. Trends in Endocrinology and Metabolism, 2016, 27, 455-469.	3.1	67
161	Mechanisms of Pediatric Inflammatory Bowel Disease. Annual Review of Immunology, 2016, 34, 31-64.	9.5	124
162	Impaired postprandial lipemic response in chronic kidney disease. Kidney International, 2016, 90, 172-180.	2.6	14
163	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 206-212.	0.9	71
164	Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipaseâ€"Independent Effects. Circulation: Cardiovascular Genetics, 2016, 9, 231-239.	5.1	28
165	Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes. Journal of Lipid Research, 2016, 57, 1601-1607.	2.0	20
166	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.4	1,189

#	Article	IF	Citations
167	Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?. Current Atherosclerosis Reports, 2016, 18, 59.	2.0	60
168	Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. Postgraduate Medicine, 2016, 128, 859-864.	0.9	7
169	On Robust Association Testing for Quantitative Traits and Rare Variants. G3: Genes, Genomes, Genetics, 2016, 6, 3941-3950.	0.8	11
171	Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy. Nanomedicine, 2016, 11, 2735-2751.	1.7	18
172	Guidelines for Large-Scale Sequence-Based Complex Trait Association Studies: Lessons Learned from the NHLBI Exome Sequencing Project. American Journal of Human Genetics, 2016, 99, 791-801.	2.6	79
173	Vascular proteomics in metabolic and cardiovascular diseases. Journal of Internal Medicine, 2016, 280, 325-338.	2.7	39
174	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	1.0	2,393
175	Triglyceride Treatment in the Age of Cholesterol Reduction. Progress in Cardiovascular Diseases, 2016, 59, 107-118.	1.6	11
176	APOC3 induces endothelial dysfunction through TNF-Î± and JAM-1. Lipids in Health and Disease, 2016, 15, 153.	1.2	22
177	The effect of omega-3 carboxylic acids on apolipoprotein CIIIâ^'containing lipoproteins in severe hypertriglyceridemia. Journal of Clinical Lipidology, 2016, 10, 1442-1451.e4.	0.6	22
178	Impact of a Genetic Risk Score on Myocardial Infarction Risk Across Different Ethnic Populations. Canadian Journal of Cardiology, 2016, 32, 1440-1446.	0.8	18
179	Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins and Other Lipid Mediators, 2016, 125, 57-64.	1.0	37
180	Association of Exome Sequences With Cardiovascular Traits Among Blacks in the Jackson Heart Study. Circulation: Cardiovascular Genetics, 2016, 9, 368-374.	5.1	8
181	Treatment of Hyperlipidemia Changes With Level of Kidney Functionâ€"Rationale. Advances in Chronic Kidney Disease, 2016, 23, 247-254.	0.6	8
182	Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms. Bioanalysis, 2016, 8, 1623-1633.	0.6	17
183	Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis, 2016, 253, 171-177.	0.4	42
184	Targeting ApoC-III to Reduce Coronary Disease Risk. Current Atherosclerosis Reports, 2016, 18, 54.	2.0	31
185	PGRNseq. Pharmacogenetics and Genomics, 2016, 26, 161-168.	0.7	93

#	Article	IF	Citations
186	Genome editing: the road of CRISPR/Cas9 from bench to clinic. Experimental and Molecular Medicine, 2016, 48, e265-e265.	3.2	74
187	Using human genetics to discover new therapeutic targets for plasma lipids. Journal of Internal Medicine, 2016, 280, 487-495.	2.7	5
188	An APOC3 3â€²UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site. Scientific Reports, 2016, 6, 32700.	1.6	21
189	The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism. Lipids in Health and Disease, 2016, 15, 184.	1.2	40
190	The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation. Nature Communications, 2016, 7, 12848.	5.8	34
191	Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension. Advances in Experimental Medicine and Biology, 2016, 956, 61-84.	0.8	172
192	Loss-of-function variants influence the human serum metabolome. Science Advances, 2016, 2, e1600800.	4.7	46
193	Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3â€²UTR variant SstI. Atherosclerosis, 2016, 255, 6-10.	0.4	6
194	Mendelian randomization analysis of a timeâ€varying exposure for binary disease outcomes using functional data analysis methods. Genetic Epidemiology, 2016, 40, 744-755.	0.6	13
195	Apolipoprotein CIII is a new player in diabetes. Current Opinion in Lipidology, 2016, 28, 1.	1.2	22
196	Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care, 2016, 39, 1408-1415.	4.3	130
197	Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovascular Diabetology, 2016, 15, 11.	2.7	28
198	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. Wiener Klinische Wochenschrift, 2016, 128, 216-228.	1.0	8
199	Very low-depth sequencing in a founder population identifies a cardioprotectiveAPOC3signal missed by genome-wide imputation. Human Molecular Genetics, 2016, 25, 2360-2365.	1.4	21
200	Apoprotein C-III: A review of its clinical implications. Clinica Chimica Acta, 2016, 460, 50-54.	0.5	18
201	The Future of Cardiovascular Therapeutics. Circulation, 2016, 133, 2610-2617.	1.6	22
202	Pathway and network-based strategies to translate genetic discoveries into effective therapies. Human Molecular Genetics, 2016, 25, R94-R98.	1.4	33
203	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes, 2016, 65, 1767-1778.	0.3	155

#	Article	IF	Citations
205	Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury. Molecular and Cellular Proteomics, 2016, 15, 2628-2640.	2.5	97
206	Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis. Meta Gene, 2016, 9, 104-109.	0.3	10
207	Insights into metabolic disease from studying genetics in isolated populations: stories from Greece to Greenland. Diabetologia, 2016, 59, 938-941.	2.9	8
208	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. Journal of Clinical Lipidology, 2016, 10, 635-645.e1.	0.6	35
209	The Advent of High-Throughput Sequencing Studies of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1323-1324.	2.5	1
210	Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice. Journal of Biological Chemistry, 2016, 291, 14695-14705.	1.6	11
211	Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. Lipids in Health and Disease, 2016, 15, 66.	1.2	7
212	Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. Cardiovascular Drugs and Therapy, 2016, 30, 65-74.	1.3	11
213	Endoscopic ultrasound-guided choledochoduodenostomy with a lumen-apposing, self-expandable fully covered metal stent for palliative biliary drainage. Clinical Journal of Gastroenterology, 2016, 9, 79-85.	0.4	12
214	Whole-exome sequencing in individuals with multiple cardiovascular risk factors and normal coronary arteries. Coronary Artery Disease, 2016, 27, 257-266.	0.3	13
215	Whole-exome sequencing for the discovery of rare genetic variants that protect from coronary artery disease. Coronary Artery Disease, 2016, 27, 253-254.	0.3	0
216	Genetics of atrial fibrillation: from families to genomes. Journal of Human Genetics, 2016, 61, 61-70.	1.1	83
217	Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 41-49.	1.3	10
218	D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nature Communications, 2016, 7, 10353.	5.8	50
219	The effect of phenotypic outliers and non-normality on rare-variant association testing. European Journal of Human Genetics, 2016, 24, 1188-1194.	1.4	39
220	History and future of omega-3 fatty acids in cardiovascular disease. Current Medical Research and Opinion, 2016, 32, 301-311.	0.9	29
221	Mendelian randomization to assess causal effects of blood lipids on coronary heart disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 124-130.	1.2	58
222	Systemic and renal lipids in kidney disease development and progression. American Journal of Physiology - Renal Physiology, 2016, 310, F433-F445.	1.3	97

#	Article	IF	Citations
223	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circulation Research, 2016, 118, 579-585.	2.0	131
224	Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics. Trends in Molecular Medicine, 2016, 22, 328-340.	3.5	27
225	New Era of Lipid-Lowering Drugs. Pharmacological Reviews, 2016, 68, 458-475.	7.1	45
226	Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 374, 1123-1133.	13.9	411
227	Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. Journal of Clinical Lipidology, 2016, 10, 905-914.	0.6	54
229	The Geisinger MyCode community health initiative: an electronic health recordâ€"linked biobank for precision medicine research. Genetics in Medicine, 2016, 18, 906-913.	1.1	340
230	Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. Journal of Lipid Research, 2016, 57, 706-713.	2.0	83
231	From Lipids to Inflammation. Circulation Research, 2016, 118, 732-749.	2.0	180
232	Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. Atherosclerosis, 2016, 247, 161-169.	0.4	34
233	From Loci to Biology. Circulation Research, 2016, 118, 586-606.	2.0	54
234	Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. Circulation Research, 2016, 118, 547-563.	2.0	701
235	New Therapeutic Approaches to the Treatment of Dyslipidemia. Cell Metabolism, 2016, 23, 405-412.	7.2	67
236	Experimental Biology for the Identification of Causal Pathways in Atherosclerosis. Cardiovascular Drugs and Therapy, 2016, 30, 1-11.	1.3	5
237	Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial. Journal of Clinical Lipidology, 2016, 10, 181-191.e2.	0.6	20
238	Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 804-814.	1.8	36
239	Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. Molecular and Cellular Proteomics, 2016, 15, 1083-1093.	2.5	23
240	Slippery Slope of Triglycerides. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 97-99.	0.9	4
241	Genetics of Coronary Artery Disease. Circulation Research, 2016, 118, 564-578.	2.0	288

#	Article	IF	Citations
242	Cardiovascular risk reduction: the future of cholesterol lowering drugs. Current Opinion in Pharmacology, 2016, 27, 62-69.	1.7	7
243	Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 100-108.	0.9	138
244	Exome Sequencing Analysis in Severe, Early-Onset Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1353-1363.	2.5	46
245	A novel mutation and a known mutation in the CLCN7 gene associated with relatively stable infantile malignant osteopetrosis in a Chinese patient. Gene, 2016, 576, 176-181.	1.0	13
246	Molecular genetics of coronary artery disease. Journal of Human Genetics, 2016, 61, 71-77.	1.1	69
247	Cardiovascular pharmacogenomics: current status and future directions. Journal of Human Genetics, 2016, 61, 79-85.	1.1	25
248	Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. Canadian Journal of Cardiology, 2017, 33, 872-882.	0.8	34
249	Genetics for the Identification of Lipid Targets Beyond PCSK9. Canadian Journal of Cardiology, 2017, 33, 334-342.	0.8	8
250	Bayesian Variable Selection for Post-Analytic Interrogation of Susceptibility Loci. Biometrics, 2017, 73, 603-614.	0.8	1
251	APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice. Journal of Biological Chemistry, 2017, 292, 3692-3705.	1.6	13
252	The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities. Current Atherosclerosis Reports, 2017, 19, 6.	2.0	38
253	From exomes to genomes: challenges and solutions in population-based genetic association studies. European Journal of Human Genetics, 2017, 25, 395-396.	1.4	4
254	Genetics of coronary artery disease: discovery, biology and clinical translation. Nature Reviews Genetics, 2017, 18, 331-344.	7.7	448
255	Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine. Journal of Lipid Research, 2017, 58, 853-865.	2.0	31
256	Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2017, 317, 937.	3.8	148
257	Very-Low-Density Lipoproteinâ€“Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by InhibitionÂofÂAPOC-III. Journal of the American College of Cardiology, 2017, 69, 789-800.	1.2	150
258	Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. Aids, 2017, 31, 965-971.	1.0	4
259	Human genes lost and their functions found. Nature, 2017, 544, 171-172.	13.7	2

#	Article	IF	Citations
260	Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature, 2017, 544, 235-239.	13.7	292
261	The State of Cardiovascular Genomics: Abundant Data, Limited Information. Revista Espanola De Cardiologia (English Ed), 2017, 70, 696-698.	0.4	0
262	Genetics of Dyslipidemia and Ischemic Heart Disease. Current Cardiology Reports, 2017, 19, 46.	1.3	19
263	A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. European Journal of Internal Medicine, 2017, 41, 10-17.	1.0	14
264	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circulation Research, 2017, 121, 81-88.	2.0	68
265	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1206-1212.	1.1	56
266	Human genetic insights into lipoproteins and risk of cardiometabolic disease. Current Opinion in Lipidology, 2017, 28, 113-119.	1.2	12
267	The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications. Revista Espanola De Cardiologia (English Ed), 2017, 70, 754-762.	0.4	6
268	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation, 2017, 136, e1-e23.	1.6	884
269	Clarifying complex inheritance. Current Opinion in Lipidology, 2017, 28, 308-312.	1.2	7
270	Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk. American Journal of Epidemiology, 2017, 186, 736-744.	1.6	28
271	RNA Activation. Advances in Experimental Medicine and Biology, 2017, , .	0.8	1
272	The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia. Atherosclerosis Supplements, 2017, 30, 19-27.	1.2	32
273	Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future. Expert Review of Clinical Pharmacology, 2017, 10, 865-873.	1.3	70
274	Genetics of Triglycerides and the Risk of Atherosclerosis. Current Atherosclerosis Reports, 2017, 19, 31.	2.0	89
275	Triglycerides Revisited to the Serial. Advances in Clinical Chemistry, 2017, 80, 1-44.	1.8	7
276	Apolipoprotein C-III. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1013-1014.	1.1	7
277	Coronary Artery Disease and Myocardial Infarction. , 2017, , 127-163.		0

#	Article	IF	Citations
278	The impact of rare and low-frequency genetic variants in common disease. Genome Biology, 2017, 18, 77.	3.8	277
279	Genetics and Valve Calcification â^—. Journal of the American College of Cardiology, 2017, 69, 2949-2951.	1.2	1
280	Association of Triglyceride-Related Genetic Variants With MitralÂAnnularÂCalcification. Journal of the American College of Cardiology, 2017, 69, 2941-2948.	1.2	25
282	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 69, 2054-2063.	1.2	348
283	Association of apolipoprotein-CIII (apoC-III), endothelium-dependent vasodilation and peripheral neuropathy in a multi-ethnic population with type 2 diabetes. Metabolism: Clinical and Experimental, 2017, 72, 75-82.	1.5	9
284	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DMâ€"INSULIN trial. Diabetes and Metabolism, 2017, 43, 453-459.	1.4	15
285	Triglycerides: A reappraisal. Trends in Cardiovascular Medicine, 2017, 27, 428-432.	2.3	12
286	Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III. Journal of Lipid Research, 2017, 58, 1196-1203.	2.0	16
287	Genetic association studies in cardiovascular diseases: Do we have enough power?. Trends in Cardiovascular Medicine, 2017, 27, 397-404.	2.3	17
288	Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids. Endocrine Practice, 2017, 23, 100-112.	1.1	39
289	Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects. Journal of Clinical Lipidology, 2017, 11, 495-506.e3.	0.6	14
290	Prediction of Cardiovascular Disease by the Framinghamâ€REGICOR Equation in the Highâ€Risk PREDIMED Cohort: Impact of the Mediterranean Diet Across Different Risk Strata. Journal of the American Heart Association, 2017, 6, .	1.6	17
291	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Advances in Therapy, 2017, 34, 300-323.	1.3	37
292	Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association. Circulation, 2017, 136, e393-e423.	1.6	732
293	Intermediate and low abundant protein analysis of vitamin D deficient obese and non-obese subjects by MALDI-profiling. Scientific Reports, 2017, 7, 12633.	1.6	10
294	Biomarkers of Cardiovascular Disorders. , 2017, , 611-672.		0
295	Antisense oligonucleotides targeting translation inhibitory elements in 5â€² UTRs can selectively increase protein levels. Nucleic Acids Research, 2017, 45, 9528-9546.	6.5	83
296	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. Journal of Lipid Research, 2017, 58, 2188-2196.	2.0	32

#	Article	IF	Citations
297	Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia. Journal of Clinical Lipidology, 2017, 11, 1361-1371.	0.6	12
298	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Current Diabetes Reports, 2017, 17, 112.	1.7	22
299	ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. British Journal of Cancer, 2017, 117, 1798-1809.	2.9	35
300	A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nature Medicine, 2017, 23, 1086-1094.	15.2	88
301	Strategies for the use of nonstatin therapies. Current Opinion in Lipidology, 2017, 28, 458-464.	1.2	2
302	Personalized Management of Cardiovascular Disorders. Medical Principles and Practice, 2017, 26, 399-414.	1.1	18
303	A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors. Scientific Reports, 2017, 7, 10252.	1.6	16
304	Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1956-1962.	1.1	33
305	Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Circulation Research, 2017, 121, e53-e79.	2.0	69
306	Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e131-e157.	1.1	262
307	Navigating the Future of Cardiovascular Drug Developmentâ€"Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovascular Drugs and Therapy, 2017, 31, 445-458.	1.3	8
309	SituaciÃ³n actual en genÃ³mica cardiovascular: muchos datos, poca informaciÃ³n. Revista Espanola De Cardiologia, 2017, 70, 696-698.	0.6	0
310	In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1741-1747.	1.1	181
311	Kidney function is associated with an altered protein composition of high-density lipoprotein. Kidney International, 2017, 92, 1526-1535.	2.6	37
312	ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Scientific Reports, 2017, 7, 2312.	1.6	47
313	A Novel Role for RARÎ± Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening. Scientific Reports, 2017, 7, 5824.	1.6	10
314	What are the prospects of apolipoprotein profiling for cardiovascular disease?. Expert Review of Molecular Diagnostics, 2017, 17, 805-807.	1.5	2
315	Human proteoforms as new targets for clinical mass spectrometry protein tests. Expert Review of Proteomics, 2017, 14, 691-699.	1.3	11

#	Article	IF	Citations
316	Genome Editing. Journal of the American College of Cardiology, 2017, 70, 2808-2821.	1.2	27
317	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. Current Atherosclerosis Reports, 2017, 19, 62.	2.0	41
318	Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a). Current Pharmacology Reports, 2017, 3, 458-468.	1.5	3
319	Mechanistic insights from combining genomics with metabolomics. Current Opinion in Lipidology, 2017, 28, 99-103.	1.2	4
320	Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL. Journal of Lipid Research, 2017, 58, 1893-1902.	2.0	39
321	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. Current Cardiology Reports, 2017, 19, 61.	1.3	12
322	The genomic landscape of African populations in health and disease. Human Molecular Genetics, 2017, 26, R225-R236.	1.4	64
323	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular Diabetology, 2017, 16, 70.	2.7	25
324	Review of radiological classifications of pancreatic cancer with peripancreatic vessel invasion: are new grading criteria required?. Cancer Imaging, 2017, 17, 14.	1.2	16
325	Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nature Genetics, 2017, 49, 17-26.	9.4	452
326	Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases. Drug Discovery Today, 2017, 22, 352-365.	3.2	41
327	New Drugs for Atherosclerosis. Canadian Journal of Cardiology, 2017, 33, 350-357.	0.8	21
328	Leveraging human genetics to guide drug target discovery. Trends in Cardiovascular Medicine, 2017, 27, 352-359.	2.3	26
329	PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nature Reviews Endocrinology, 2017, 13, 36-49.	4.3	509
330	Identity-by-Descent Mapping Identifies Major Locus for Serum Triglycerides in Amerindians Largely Explained by an APOC3 Founder Mutation. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	21
331	Genome-wide association study identifies a missense variant at APOA5 for coronary artery disease in Multi-Ethnic Cohorts from Southeast Asia. Scientific Reports, 2017, 7, 17921.	1.6	28
332	An Ecosystem Perspective On Asset Management Information. Management Systems in Production Engineering, 2017, 25, 150-157.	0.4	6
333	Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Oncotarget, 2017, 8, 12333-12341.	0.8	8

#	Article	IF	Citations
334	Role of Intestinal LXRÎ± in Regulating Post-prandial Lipid Excursion and Diet-Induced Hypercholesterolemia and Hepatic Lipid Accumulation. Frontiers in Physiology, 2017, 8, 280.	1.3	13
335	Quinoa Seed Lowers Serum Triglycerides in Overweight and Obese Subjects: A Dose-Response Randomized Controlled Clinical Trial. Current Developments in Nutrition, 2017, 1, e001321.	0.1	38
336	Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-18.	1.9	29
337	Deficient Cholesterol Esterification in Plasma of apoc2 Knockout Zebrafish and Familial Chylomicronemia Patients. PLoS ONE, 2017, 12, e0169939.	1.1	9
338	Enrichment of colorectal cancer associations in functional regions: Insight for using epigenomics data in the analysis of whole genome sequence-imputed GWAS data. PLoS ONE, 2017, 12, e0186518.	1.1	8
339	Rare coding variants pinpoint genes that control human hematological traits. PLoS Genetics, 2017, 13, e1006925.	1.5	39
340	Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids in Health and Disease, 2017, 16, 149.	1.2	96
341	Rare non-coding variants are associated with plasma lipid traits in a founder population. Scientific Reports, 2017, 7, 16415.	1.6	31
343	Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee. Journal of Lipids, 2017, 2017, 1-7.	1.9	10
344	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
345	Genetic Influences on Blood Lipids and Cardiovascular Disease Risk. , 2017, , 571-593.		1
346	Lipid metabolism. Current Opinion in Lipidology, 2018, 29, 164-165.	1.2	2
347	How genome editing could be used in the treatment of cardiovascular diseases. Personalized Medicine, 2018, 15, 67-69.	0.8	7
348	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 2018, 138, 770-781.	1.6	126
349	Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1542-1550.	1.4	10
350	Insights from population-based analyses of plasma lipids across the allele frequency spectrum. Current Opinion in Genetics and Development, 2018, 50, 1-6.	1.5	9
351	Update on the laboratory investigation of dyslipidemias. Clinica Chimica Acta, 2018, 479, 103-125.	0.5	38
352	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Lipidology, 2018, 12, 801-809.	0.6	19

#	Article	IF	Citations
353	Heart Disease and Stroke Statisticsâ€"2018 Update: A Report From the American Heart Association. Circulation, 2018, 137, e67-e492.	1.6	5,228
354	Advances in lipid-lowering therapy through gene-silencing technologies. Nature Reviews Cardiology, 2018, 15, 261-272.	6.1	101
355	APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 660-668.	1.1	70
356	Genetics and Genomics of Coronary Artery Disease. , 2018, , 661-678.		1
357	Genetics of familial hypercholesterolemia. Current Opinion in Lipidology, 2018, 29, 80-86.	1.2	5
358	Effects of evolving lipid-lowering drugs on carbohydrate metabolism. Diabetes Research and Clinical Practice, 2018, 137, 1-9.	1.1	2
359	Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome. Expert Opinion on Orphan Drugs, 2018, 6, 141-149.	0.5	4
360	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. Canadian Journal of Cardiology, 2018, 34, 595-604.	0.8	56
361	Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studiesâ€"Statement From ATVB Council. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 292-303.	1.1	221
362	Pharmacogenomics of blood lipid regulation. Pharmacogenomics, 2018, 19, 651-665.	0.6	3
363	Control of serum triglyceride levels by the apolipoprotein C3 gene and its relationship to cardiovascular disease. Current Opinion in Lipidology, 2018, 29, 271-272.	1.2	2
364	Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease. Scientific Reports, 2018, 8, 6752.	1.6	38
365	Opportunities and Challenges in Cardiovascular Pharmacogenomics. Circulation Research, 2018, 122, 1176-1190.	2.0	23
366	Triglyceride-Rich Lipoproteins. Cardiology Clinics, 2018, 36, 265-275.	0.9	16
367	A decade of genome-wide association studies for coronary artery disease: the challenges ahead. Cardiovascular Research, 2018, 114, 1241-1257.	1.8	217
368	New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?. Atherosclerosis, 2018, 272, 27-32.	0.4	30
369	Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes. Stroke, 2018, 49, 820-827.	1.0	132
370	Lipoprotein Disorders. , 2018, , 27-46.		1

#	Article	IF	Citations
371	Proprotein convertase subtilisin/kexin type 9. Current Opinion in Cardiology, 2018, 33, 269-275.	0.8	12
372	Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Current Opinion in Lipidology, 2018, 29, 171-179.	1.2	75
373	Genomics to Predict Risk of Coronary Artery Disease. , 2018, , 127-146.		0
374	HighâEDensity Lipoprotein Subspecies Defined by Apolipoprotein CâEIII and Subclinical Atherosclerosis Measures: MESA (The Multiâ€Ethnic Study of Atherosclerosis). Journal of the American Heart Association, 2018, 7, .	1.6	19
375	CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 12-18.	1.1	23
376	Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia. Journal of Pharmaceutical Investigation, 2018, 48, 233-241.	2.7	3
377	High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts. Circulation, 2018, 137, 1364-1373.	1.6	85
378	Genetic architecture: the shape of the genetic contribution to human traits and disease. Nature Reviews Genetics, 2018, 19, 110-124.	7.7	335
379	Efficacy and safety of pemafibrate (K-877), aÂselective peroxisome proliferator-activated receptor Î± modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. Journal of Clinical Lipidology, 2018, 12, 173-184.	0.6	127
380	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2018, 8, e021508.	0.8	14
381	hiPSC-Based Tissue Organoid Regeneration. , 0, , .		2
382	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circulation Journal, 2018, 48, 1097.	0.7	15
383	Cohort-wide deep whole genome sequencing and the allelic architecture of complex traits. Nature Communications, 2018, 9, 4674.	5.8	33
384	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies. Nutrients, 2018, 10, 1789.	1.7	32
385	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. BMC Cancer, 2018, 18, 1103.	1.1	25
386	Association between Genetic Variant of Apolipoprotein C3 and Incident Hypertension Stratified by Obesity and Physical Activity in Korea. Nutrients, 2018, 10, 1595.	1.7	4
387	Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study. Lipids in Health and Disease, 2018, 17, 273.	1.2	14
388	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. Journal of Clinical Lipidology, 2018, 12, 1493-1501.e11.	0.6	7

#	Article	IF	Citations
389	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature Genetics, 2018, 50, 1514-1523.	9.4	497
390	Frequency and phenotype consequence of APOC3 rare variants in patients with very low triglyceride levels. BMC Medical Genomics, 2018, 11, 66.	0.7	5
391	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	1.2	276
392	Absence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis. JCI Insight, 2018, 3, .	2.3	91
393	Genetics of Coronary Atherosclerosis. , 2018, , 33-44.		0
394	RNA-targeted therapeutics for lipid disorders. Current Opinion in Lipidology, 2018, 29, 459-466.	1.2	54
395	Beyond Statins: Who and When to Prescribe?. Current Diabetes Reports, 2018, 18, 126.	1.7	4
396	Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2018, 11, e000046.	1.6	10
397	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Realâ€World Administrative Claims Analysis of Statinâ€Treated Patients With High Residual Cardiovascular Risk. Journal of the American Heart Association, 2018, 7, e008740.	1.6	81
398	Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice. Lipids in Health and Disease, 2018, 17, 220.	1.2	20
399	Association of Genetically Enhanced Lipoprotein Lipaseâ€“Mediated Lipolysis and Low-Density Lipoprotein Cholesterolâ€“Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. JAMA Cardiology, 2018, 3, 957.	3.0	55
400	OBSOLETE: Bioinformatics Principles for Deciphering Cardiovascular Diseases. , 2018, , .		1
401	Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. Annals of Surgical Oncology, 2018, 25, 3492-3501.	0.7	4
402	APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia. Current Medicinal Chemistry, 2018, 25, 1567-1576.	1.2	34
403	The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. Matrix Biology, 2018, 71-72, 262-282.	1.5	36
404	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry, 2018, 64, 1006-1033.	1.5	189
405	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. Journal of Lipid Research, 2018, 59, 1266-1275.	2.0	62
406	Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis, 2018, 274, 182-190.	0.4	12

#	Article	IF	Citations
407	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. Clinical Pharmacology and Therapeutics, 2018, 104, 244-256.	2.3	14
408	Bioinformatics Principles for Deciphering Cardiovascular Diseases. , 2018, , 273-292.		3
409	Low-Density Lipoprotein Triglycerides. Journal of the American College of Cardiology, 2018, 72, 170-172.	1.2	10
410	Unmet Need for AdjunctiveÂDyslipidemiaÂTherapy in Hypertriglyceridemia Management. Journal of the American College of Cardiology, 2018, 72, 330-343.	1.2	152
411	Novel Therapeutic Targets for Managing Dyslipidemia. Trends in Pharmacological Sciences, 2018, 39, 733-747.	4.0	31
412	Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 237-242.	1.4	6
413	Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism. Lipids in Health and Disease, 2018, 17, 160.	1.2	9
414	Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. Journal of the American College of Cardiology, 2018, 72, 300-310.	1.2	69
415	Proper conditional analysis in the presence of missing data: Application to large scale meta-analysis of tobacco use phenotypes. PLoS Genetics, 2018, 14, e1007452.	1.5	18
416	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. Current Cardiology Reports, 2018, 20, 88.	1.3	18
417	RNA Therapeutics in Cardiovascular Precision Medicine. Frontiers in Physiology, 2018, 9, 953.	1.3	63
418	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Annals of Medicine, 2018, 50, 565-575.	1.5	36
419	Assessment of omegaâ€3 carboxylic acids in statinâ€treated patients with high levels of triglycerides and low levels of highâ€density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clinical Cardiology, 2018, 41, 1281-1288.	0.7	151
420	Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Medicine, 2018, 16, 125.	2.3	95
421	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). International Journal of Epidemiology, 2018, 47, 380-381j.	0.9	59
422	HDL-cholesterol, genetics, and coronary artery disease: the myth of the â€˜good cholesterolâ€™?. European Heart Journal, 2018, 39, 2179-2182.	1.0	15
423	Human Genetics of Obesity and Type 2 Diabetes Mellitus. Circulation Genomic and Precision Medicine, 2018, 11, e002090.	1.6	58
424	Assessing Rare Variation in Complex Traits. Methods in Molecular Biology, 2018, 1793, 51-71.	0.4	4

#	Article	IF	Citations
425	Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. Angiology, 2019, 70, 197-209.	0.8	18
426	Increased triglyceride/high-density lipoprotein cholesterol ratio may be associated with reduction in the low-density lipoprotein particle size: assessment of atherosclerotic cardiovascular disease risk. Heart and Vessels, 2019, 34, 227-236.	0.5	19
427	Genetic Variations, Triglycerides, and Atherosclerotic Disease. Journal of Atherosclerosis and Thrombosis, 2019, 26, 128-131.	0.9	11
428	Plasma Proteome Profiles of Stable CAD Patients Stratified According to Total Apo Câ€III Levels. Proteomics - Clinical Applications, 2019, 13, e1800023.	0.8	3
429	Family-Based Quantitative Trait Meta-Analysis Implicates Rare Noncoding Variants in DENND1A in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3835-3850.	1.8	51
430	ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2145-2156.	1.1	20
431	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation, 2019, 140, e673-e691.	1.6	282
432	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet, The, 2019, 394, 697-708.	6.3	67
433	Pharmacogenomics. Lancet, The, 2019, 394, 521-532.	6.3	261
434	The Future of Lipid-lowering Therapy. Journal of Clinical Medicine, 2019, 8, 1085.	1.0	8
435	TIMD4 rs6882076 SNP Is Associated with Decreased Levels of Triglycerides and the Risk of Coronary Heart Disease and Ischemic Stroke. International Journal of Medical Sciences, 2019, 16, 864-871.	1.1	9
436	A little more time around the track may go a long way: Implications of increasing moderate to vigorous physical activity in pre-adolescents. Atherosclerosis, 2019, 288, 160-162.	0.4	0
437	Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation, 2019, 140, 470-486.	1.6	170
438	Life is complicated: so is apoCIII. Journal of Lipid Research, 2019, 60, 1347-1349.	2.0	6
439	Rounding the corner on residual risk: Implications of REDUCEâ€IT for omegaâ€3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. Clinical Cardiology, 2019, 42, 829-838.	0.7	13
440	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Journal of Clinical Lipidology, 2019, 13, 860-872.	0.6	79
441	Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e1-e9.	1.1	45
442	A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacological Research, 2019, 150, 104413.	3.1	70

#	Article	IF	Citations
443	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. Mayo Clinic Proceedings, 2019, 94, 1670-1680.	1.4	45
444	Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma. EJNMMI Research, 2019, 9, 24.	1.1	7
445	2018 George Lyman Duff Memorial Lecture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1925-1937.	1.1	6
446	Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Medical Oncology, 2019, 36, 87.	1.2	12
447	Investigating Coronary Artery Disease methylome through targeted bisulfite sequencing. Gene, 2019, 721, 144107.	1.0	10
448	Heart Disease and Stroke Statisticsâ€”2019 Update: A Report From the American Heart Association. Circulation, 2019, 139, e56-e528.	1.6	6,192
449	Lipid-Lowering Agents. Circulation Research, 2019, 124, 386-404.	2.0	124
450	Moving Targets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 349-359.	1.1	31
451	Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference. Journal of Lipid Research, 2019, 60, 805-818.	2.0	19
452	Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. Current Atherosclerosis Reports, 2019, 21, 27.	2.0	72
453	Targeting RNA to lower triglycerides: long strides from short molecules. European Heart Journal, 2019, 40, 2797-2800.	1.0	10
454	ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. Journal of Lipid Research, 2019, 60, 1379-1395.	2.0	48
455	Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. Current Cardiology Reports, 2019, 21, 68.	1.3	49
456	Emerging Concepts in Precision Medicine and Cardiovascular Diseases in Racial and Ethnic Minority Populations. Circulation Research, 2019, 125, 7-13.	2.0	37
457	ANGPTL4 in Metabolic and Cardiovascular Disease. Trends in Molecular Medicine, 2019, 25, 723-734.	3.5	118
458	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	2.7	104
459	Management of diabetic dyslipidemia: An update. World Journal of Diabetes, 2019, 10, 280-290.	1.3	58
460	The effects of oleoylethanolamide, an endogenous PPARâ€Îł± agonist, on risk factors for NAFLD: A systematic review. Obesity Reviews, 2019, 20, 1057-1069.	3.1	35

#	Article	IF	Citations
461	Elevated triglycerides rather than other lipid parameters are associated with increased urinary albumin to creatinine ratio in the general population of China: a report from the REACTION study. Cardiovascular Diabetology, 2019, 18, 57.	2.7	13
462	Implementation of public health genomics in Pakistan. European Journal of Human Genetics, 2019, 27, 1485-1492.	1.4	19
463	Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity. Cell, 2019, 177, 597-607.e9.	13.5	192
464	Residual cardiovascular risk among people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 28-38.	2.2	31
465	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 6-16.	2.2	13
466	Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death. Journal of the American College of Cardiology, 2019, 73, 2135-2145.	1.2	26
467	A Novel Biomarker Approach to ExploitÂHDL for Risk Assessment. Journal of the American College of Cardiology, 2019, 73, 2146-2149.	1.2	1
468	FunSPU: A versatile and adaptive multiple functional annotation-based association test of whole-genome sequencing data. PLoS Genetics, 2019, 15, e1008081.	1.5	16
469	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry, 2019, 56, 338-356.	0.8	27
470	Triglycerides: Mendelian Randomization Studies Suggest Causal Role, but How to Treat in 2019?. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	0
471	Triglycerides and cardiovascular risk: Apolipoprotein B holds the key. Atherosclerosis, 2019, 284, 221-222.	0.4	15
472	Genetics of Common, Complex Coronary Artery Disease. Cell, 2019, 177, 132-145.	13.5	166
473	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocrine Reviews, 2019, 40, 537-557.	8.9	262
474	Methods for the Analysis and Interpretation for Rare Variants Associated with Complex Traits. Current Protocols in Human Genetics, 2019, 101, e83.	3.5	11
475	2018 Curt Stern Award Address. American Journal of Human Genetics, 2019, 104, 384-388.	2.6	0
476	Role of apolipoprotein Câ€III overproduction in diabetic dyslipidaemia. Diabetes, Obesity and Metabolism, 2019, 21, 1861-1870.	2.2	39
477	A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk. Journal of Clinical Lipidology, 2019, 13, 492-501.	0.6	3
478	Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis. Diabetologia, 2019, 62, 981-992.	2.9	22

#	Article	IF	Citations
479	LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. Journal of Experimental and Clinical Cancer Research, 2019, 38, 75.	3.5	44
480	Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency. Journal of Clinical Lipidology, 2019, 13, 317-325.	0.6	20
481	Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study. EBioMedicine, 2019, 41, 85-90.	2.7	33
482	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. Current Diabetes Reports, 2019, 19, 13.	1.7	32
483	Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia â€“ spotlight on volanesorsen. Expert Opinion on Investigational Drugs, 2019, 28, 389-394.	1.9	10
484	Completing the genetic spectrum influencing coronary artery disease: from germline to somatic variation. Cardiovascular Research, 2019, 115, 830-843.	1.8	14
485	Alternative Natural Management of Dyslipidemia. , 0, , .		1
486	Sequence analysis and variant identification at the APOC3 gene locus indicates association of rs5218 with BMI in a sample of Kuwaitiâ€™s. Lipids in Health and Disease, 2019, 18, 224.	1.2	1
487	Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. New England Journal of Medicine, 2019, 381, 2582-2584.	13.9	21
488	Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. Expert Opinion on Investigational Drugs, 2019, 28, 1059-1079.	1.9	3
489	Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease. Lipids in Health and Disease, 2019, 18, 220.	1.2	21
490	Cannabis effects on lipoproteins. Current Opinion in Lipidology, 2019, 30, 140-146.	1.2	15
491	Inheritance of high and low HDL: mechanisms and management. Current Opinion in Lipidology, 2019, 30, 307-313.	1.2	9
492	Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 109-116.	1.2	36
493	Remnant lipoproteins and atherosclerotic cardiovascular disease. Clinica Chimica Acta, 2019, 490, 1-5.	0.5	23
494	Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cellular Signalling, 2019, 55, 53-64.	1.7	23
495	Antihypertensive Drugs and Vascular Health. Updates in Hypertension and Cardiovascular Protection, 2019, , 585-605.	0.1	0
496	Apolipoprotein C-III Strongly Correlates with Activated Factor VIIâ€“Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation. Thrombosis and Haemostasis, 2019, 119, 192-202.	1.8	17

#	Article	IF	Citations
497	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. American Journal of Cardiovascular Drugs, 2019, 19, 113-131.	1.0	4
498	DNA Sequence Variation in ACVR1C Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes. Diabetes, 2019, 68, 226-234.	0.3	31
499	Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 63-72.	1.1	61
500	Not Just Arterial Damage: Increased Incidence of Venous Thromboembolic Events in Cardiovascular Patients With Elevated Plasma Levels of Apolipoprotein CIII. Journal of the American Heart Association, 2019, 8, e010973.	1.6	9
501	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. Annual Review of Medicine, 2019, 70, 19-32.	5.0	6
503	Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease. Clinical Cardiology, 2019, 42, 56-61.	0.7	25
504	Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology, 2019, 51, 131-141.	0.3	112
505	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. Trends in Cardiovascular Medicine, 2020, 30, 151-157.	2.3	3
506	Relationship between triglyceride levels and ischaemic stroke in elderly hypertensive patients. Postgraduate Medical Journal, 2020, 96, 128-133.	0.9	12
507	Genetics and Genomics of Atherosclerotic Cardiovascular Disease. , 2020, , 209-230.		0
508	Complexity, cost, and content â€“ three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing. Clinical Chemistry and Laboratory Medicine, 2020, 58, 858-863.	1.4	2
509	Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduction and Targeted Therapy, 2020, 5, 1.	7.1	1,354
510	High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. Journal of Lipid Research, 2020, 61, 445-454.	2.0	15
511	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. European Heart Journal, 2020, 41, 2304-2312.	1.0	54
512	An adaptive test for metaâ€•analysis of rare variant association studies. Genetic Epidemiology, 2020, 44, 104-116.	0.6	2
513	Apolipoprotein B48 metabolism in chylomicrons and very lowâ€•density lipoproteins and its role in triglyceride transport in normoâ€•and hypertriglyceridemic human subjects. Journal of Internal Medicine, 2020, 288, 422-438.	2.7	25
514	Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults. JAMA Cardiology, 2020, 5, 13.	3.0	29
515	Recent developments in pharmacotherapy for hypertriglyceridemia: whatâ€™s the current state of the art?. Expert Opinion on Pharmacotherapy, 2020, 21, 107-120.	0.9	10

#	Article	IF	Citations
516	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 279-289.	2.2	33
517	Triglyceride metabolism and angiopoietin-like proteins in lipoprotein lipase regulation. Clinica Chimica Acta, 2020, 503, 19-34.	0.5	40
518	Cardioinformatics: the nexus of bioinformatics and precision cardiology. Briefings in Bioinformatics, 2020, 21, 2031-2051.	3.2	15
519	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nature Immunology, 2020, 21, 30-41.	7.0	169
520	Lipid alterations in adolescents with early-onset psychosis may be independent of antipsychotic medication. Schizophrenia Research, 2020, 216, 295-301.	1.1	10
521	A higher glycemic response to oral glucose is associated with higher plasma apolipoprotein C3 independently of BMI in healthy twins. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 459-466.	1.1	1
522	Clinical review on triglycerides. European Heart Journal, 2020, 41, 99-109c.	1.0	286
523	Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII. Current Opinion in Lipidology, 2020, 31, 20-26.	1.2	20
524	Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 656-669.	1.1	17
525	Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease. Atherosclerosis, 2020, 311, 84-90.	0.4	9
526	Hypertriglyceridemiaâ€"Causes, Significance, and Approaches to Therapy. Frontiers in Endocrinology, 2020, 11, 616.	1.5	29
527	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. American Journal of Preventive Cardiology, 2020, 3, 100086.	1.3	10
528	Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2020, 32, 209-218.	0.1	2
529	Genetic Variants Associated With Increased Plasma Levels of Triglycerides, via Effects on the Lipoprotein Lipase Pathway, Increase Risk of Acute Pancreatitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1652-1660.e6.	2.4	30
530	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Molecular Metabolism, 2020, 42, 101092.	3.0	197
531	Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. Journal of Lipid Research, 2020, 61, 1271-1286.	2.0	120
532	Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. Expert Opinion on Pharmacotherapy, 2020, 21, 1675-1684.	0.9	17
533	VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins. Journal of the American College of Cardiology, 2020, 76, 2725-2735.	1.2	105

#	Article	IF	Citations
534	AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell Reports Medicine, 2020, 1, 100057.	3.3	72
535	APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. BioMed Research International, 2020, 2020, 1-9.	0.9	6
536	Vaccination in Atherosclerosis. Cells, 2020, 9, 2560.	1.8	24
537	Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3. European Heart Journal, 2020, 41, 3946-3948.	1.0	4
538	Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2095-2107.	1.1	19
539	The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. Frontiers in Endocrinology, 2020, 11, 474.	1.5	81
540	The Positive Association between Plasma Myristic Acid and ApoCIII Concentrations in Cardiovascular Disease Patients Is Supported by the Effects of Myristic Acid in HepG2 Cells. Journal of Nutrition, 2020, 150, 2707-2715.	1.3	11
541	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. Journal of Lipid Research, 2020, 61, 1254-1262.	2.0	25
542	Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China. Lipids in Health and Disease, 2020, 19, 179.	1.2	11
543	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews, 2020, 159, 4-33.	6.6	113
544	Targeting RNA With AntisenseÂOligonucleotides and SmallÂInterfering RNA in Dyslipidemias. Journal of the American College of Cardiology, 2020, 76, 563-579.	1.2	52
545	Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models. Frontiers in Endocrinology, 2020, 11, 504.	1.5	26
546	Fibroblast growth factorÂ8 overexpression is predictive of poor prognosis in pancreatic ductal adenocarcinoma. European Surgery - Acta Chirurgica Austriaca, 2020, 52, 282-289.	0.3	4
547	ApoCIII: A multifaceted protein in cardiometabolic disease. Metabolism: Clinical and Experimental, 2020, 113, 154395.	1.5	22
548	Vitamin D3 metabolite ratio as an indicator of vitamin D status and its association with diabetes complications. BMC Endocrine Disorders, 2020, 20, 161.	0.9	17
549	Advances in Genomics for Drug Development. Genes, 2020, 11, 942.	1.0	22
550	Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?. Current Cardiology Reports, 2020, 22, 146.	1.3	6
551	Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Nature Genetics, 2020, 52, 969-983.	9.4	146

#	Article	IF	Citations
552	Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants. Genes and Diseases, 2022, 9, 370-380.	1.5	7
553	TriglicÃ©ridos, colesterol HDL y dislipidemia aterogÃ©nica en la guÃa europea para el control de las dislipidemias 2019. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2020, 32, 209-218.	0.4	3
554	Gene-based therapy in lipid management: the winding road from promise to practice. Expert Opinion on Investigational Drugs, 2020, 29, 483-493.	1.9	20
555	Treatment and Survival of Elderly Patients with Stage Iâ€“II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. Annals of Surgical Oncology, 2020, 27, 5337-5346.	0.7	9
556	Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma. PLoS Genetics, 2020, 16, e1008682.	1.5	31
557	Association Analysis and Meta-Analysis of Multi-Allelic Variants for Large-Scale Sequence Data. Genes, 2020, 11, 586.	1.0	3
558	Genomic Strategies Toward Identification of Novel Therapeutic Targets. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	3
559	EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression. IScience, 2020, 23, 100973.	1.9	8
560	Identifying functional non-coding variants in APOA5/A4/C3/A1 gene cluster associated with coronary heart disease. Journal of Molecular and Cellular Cardiology, 2020, 144, 54-62.	0.9	9
561	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Current Atherosclerosis Reports, 2020, 22, 18.	2.0	26
562	The effect of LRRK2 loss-of-function variants in humans. Nature Medicine, 2020, 26, 869-877.	15.2	79
563	Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study. Lipids in Health and Disease, 2020, 19, 116.	1.2	9
564	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Current Atherosclerosis Reports, 2020, 22, 25.	2.0	38
565	Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype. Metabolomics, 2020, 16, 69.	1.4	3
566	Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations. Circulation Research, 2020, 126, 1816-1840.	2.0	19
567	Genomics of hypertriglyceridemia. Advances in Clinical Chemistry, 2020, 97, 141-169.	1.8	10
568	A study on the correlation between remnant cholesterol and urinary albumin to creatinine ratio in Chinese community adults: A report from the <scp>REACTION</scp> study. Journal of Diabetes, 2020, 12, 870-880.	0.8	8
569	Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert Review of Cardiovascular Therapy, 2020, 18, 355-361.	0.6	25

#	Article	IF	Citations
570	Role of Rare and Low-Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels. Circulation Genomic and Precision Medicine, 2020, 13, e002772.	1.6	11
571	Gestational hypothyroidism elicits more pronounced lipid dysregulation in mice than pre-pregnant hypothyroidism. Endocrine Journal, 2020, 67, 593-605.	0.7	8
572	Fibrate pharmacogenomics: expanding past the genome. Pharmacogenomics, 2020, 21, 293-306.	0.6	7
573	Polygenic Hyperlipidemias and Coronary Artery Disease Risk. Circulation Genomic and Precision Medicine, 2020, 13, e002725.	1.6	60
574	In Search for Genes Related to Atherosclerosis and Dyslipidemia Using Animal Models. International Journal of Molecular Sciences, 2020, 21, 2097.	1.8	14
575	Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science, 2020, 368, 290-296.	6.0	714
576	Coronary Artery Disease: Therapeutics and Drug Discovery. Advances in Experimental Medicine and Biology, 2020, , .	0.8	4
577	Monocytes and Macrophages as Protagonists in Vascular Complications of Diabetes. Frontiers in Cardiovascular Medicine, 2020, 7, 10.	1.1	45
578	Low cholesterol syndrome and drug development. Current Opinion in Cardiology, 2020, 35, 423-427.	0.8	1
579	Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9. Trends in Cardiovascular Medicine, 2021, 31, 341-348.	2.3	5
580	Emerging Targets for Cardiovascular Disease Prevention in Diabetes. Trends in Molecular Medicine, 2020, 26, 744-757.	3.5	15
581	Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy. Circulation Journal, 2020, 84, 509-515.	0.7	12
582	HDL-associated apoCIII plays an independent role in predicting postprandial hypertriglyceridemia. Clinical Biochemistry, 2020, 79, 14-22.	0.8	12
583	Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL. Journal of Clinical Lipidology, 2020, 14, 241-251.	0.6	17
584	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. Heart, 2020, 106, 738-745.	1.2	28
585	Human apolipoprotein CIII levels; evaluation of three assay methods. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 230-235.	0.6	1
586	Triglycerides and residual risk. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 95-103.	1.2	42
587	Identification of dissociation factors in pancreatic Cancer using a mass spectrometry-based proteomic approach. BMC Cancer, 2020, 20, 45.	1.1	11

#	Article	IF	Citations
588	Heart Disease and Stroke Statisticsâ€"2020 Update: A Report From the American Heart Association. Circulation, 2020, 141, e139-e596.	1.6	5,545
589	Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date . Vascular Health and Risk Management, 2020, Volume 16, 1-10.	1.0	10
590	The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?. Current Opinion in Lipidology, 2020, 31, 140-146.	1.2	29
591	Analytic and Translational Genetics. Annual Review of Biomedical Data Science, 2020, 3, 217-241.	2.8	4
592	Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. European Heart Journal, 2020, 41, 2288-2299.	1.0	70
593	Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients. International Journal of Clinical Practice, 2020, 74, e13508.	0.8	9
594	Non-neoplastic hepatopancreatobiliary lesions simulating malignancy: can we differentiate?. Insights Into Imaging, 2020, 11, 21.	1.6	2
595	Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2020, 15, 147-157.	1.2	12
596	A novel NanoBiT-based assay monitors the interaction between lipoprotein lipase and GPIHBP1 in real time. Journal of Lipid Research, 2020, 61, 546-559.	2.0	12
597	Loss-of-function tolerance of enhancers in the human genome. PLoS Genetics, 2020, 16, e1008663.	1.5	12
598	Biotechnology Approaches for the Treatment of Dyslipidemia. Cardiovascular Drugs and Therapy, 2021, 35, 167-183.	1.3	4
599	Personalized medicine for cardiovascular diseases. Journal of Human Genetics, 2021, 66, 67-74.	1.1	23
600	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. Annual Review of Medicine, 2021, 72, 447-458.	5.0	12
601	Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids. Journal of the American College of Cardiology, 2021, 77, 593-608.	1.2	33
602	Polymorphisms in the CETP, APOC3 and APOE genes in men with unstable atherosclerotic plaques in the coronary arteries. Meta Gene, 2021, 27, 100847.	0.3	0
603	Unique roles of rare variants in the genetics of complex diseases in humans. Journal of Human Genetics, 2021, 66, 11-23.	1.1	74
604	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. Cardiovascular Research, 2021, 117, 1033-1045.	1.8	33
605	Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies. Molecular Biology Reports, 2021, 48, 875-886.	1.0	16

#	Article	IF	Citations
606	Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle. International Journal of Molecular Sciences, 2021, 22, 932.	1.8	12
607	Role of Genetics in Preventive Cardiology: Focused on Dyslipidemia. Korean Circulation Journal, 2021, 51, 899.	0.7	4
608	Pediatric dyslipidemias: lipoprotein metabolism disorders in children. , 2021, , 965-1022.		0
610	Enyzmes | Lipoprotein Lipase. , 2021, , 307-320.		0
611	Meta-analysis of sample-level dbGaP data reveals novel shared genetic link between body height and Crohnâ€™s disease. Human Genetics, 2021, 140, 865-877.	1.8	3
612	Biomarkers. , 2021, , 31-64.		0
613	Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. European Journal of Preventive Cardiology, 2022, 29, e53-e64.	0.8	15
614	Translating genetic association of lipid levels for biological and clinical application. Cardiovascular Drugs and Therapy, 2021, 35, 617-626.	1.3	4
615	Rare versus common diseases: a false dichotomy in precision medicine. Npj Genomic Medicine, 2021, 6, 19.	1.7	14
616	J-shaped association between circulating apoC-III and cardiovascular mortality. European Journal of Preventive Cardiology, 2022, 29, e68-e71.	0.8	2
617	Triglycerides and risk of atherosclerotic cardiovascular disease: An update. Archives of Cardiovascular Diseases, 2021, 114, 132-139.	0.7	39
618	ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Current Atherosclerosis Reports, 2021, 23, 20.	2.0	36
619	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. Cardiovascular Drugs and Therapy, 2021, 35, 677-690.	1.3	11
620	The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes. Current Atherosclerosis Reports, 2021, 23, 23.	2.0	21
621	Uncovering the role of apolipoprotein C-III in insulin resistance. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2021, 33, 108-115.	0.1	0
622	Genome-Wide Identification of Rare and Common Variants Driving Triglyceride Levels in a Nevada Population. Frontiers in Genetics, 2021, 12, 639418.	1.1	7
623	The effects of KaiXinSan on depression and its association with lipid profiles: A randomized, double-blinded, placebo-controlled trial. Phytomedicine, 2021, 83, 153467.	2.3	12
624	Uncovering the role of apolipoprotein C-III in insulin resistance. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 108-115.	0.4	3

#	Article	IF	Citations
625	Model-based assessment of replicability for genome-wide association meta-analysis. Nature Communications, 2021, 12, 1964.	5.8	24
626	Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy. BMC Surgery, 2021, 21, 110.	0.6	2
627	Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy. Laboratory Investigation, 2021, 101, 935-941.	1.7	8
628	Apolipoprotein E and Atherosclerosis. Current Atherosclerosis Reports, 2021, 23, 34.	2.0	21
629	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.4	83
631	Recent Molecular Mechanisms and Beneficial Effects of Phytochemicals and Plant-Based Whole Foods in Reducing LDL-C and Preventing Cardiovascular Disease. Antioxidants, 2021, 10, 784.	2.2	39
632	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 264-275.	5.5	109
633	A lipid loverâ€™s guide to novel therapeutics for lipid and cardiovascular risk reduction. Future Cardiology, 2021, 17, 507-520.	0.5	2
634	Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF-Î¹B pathway. Metabolism: Clinical and Experimental, 2021, 119, 154740.	1.5	18
635	Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas. International Journal of Clinical Oncology, 2021, 26, 1911-1921.	1.0	7
636	The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?. Current Atherosclerosis Reports, 2021, 23, 40.	2.0	15
637	Lipid droplet screen in human hepatocytes identifies TRRAP as a regulator of cellular triglyceride metabolism. Clinical and Translational Science, 2021, 14, 1369-1379.	1.5	4
638	Per-Particle Triglyceride-Rich Lipoproteins Imply Higher Myocardial Infarction Risk Than Low-Density Lipoproteins: Copenhagen General Population Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2063-2075.	1.1	21
639	Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases. Life, 2021, 11, 581.	1.1	11
641	Personalized medicine in cardiovascular disease: review of literature. Journal of Diabetes and Metabolic Disorders, 2021, 20, 1793-1805.	0.8	8
642	GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity. Frontiers in Cell and Developmental Biology, 2021, 9, 702508.	1.8	22
643	Who would benefit most from postprandial lipid screening?. Clinical Nutrition, 2021, 40, 4762-4771.	2.3	6
644	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. European Heart Journal, 2021, 42, 4324-4332.	1.0	135

#	Article	IF	Citations
645	Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands. Genes, 2021, 12, 1168.	1.0	12
646	Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science, 2021, 373, .	6.0	130
647	Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 685-693.	0.6	16
648	Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies. JACC Basic To Translational Science, 2021, 6, 610-623.	1.9	47
649	Is a High HDL-Cholesterol Level Always Beneficial?. Biomedicines, 2021, 9, 1083.	1.4	22
650	Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, e631-e640.	0.8	0
651	Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China. Transplant Immunology, 2022, 71, 101444.	0.6	2
652	Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. Biomedicines, 2021, 9, 985.	1.4	13
653	A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1332-1342.	1.3	2
654	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. Journal of the American College of Cardiology, 2021, 78, 960-993.	1.2	146
655	Genetics of coronary artery disease in the postâ€GWAS era. Journal of Internal Medicine, 2021, 290, 980-992.	2.7	46
656	Metabolic-associated fatty liver disease and lipoprotein metabolism. Molecular Metabolism, 2021, 50, 101238.	3.0	195
657	Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury. Journal of the American Society of Nephrology: JASN, 2021, 32, 3146-3160.	3.0	16
658	A lifestyle intervention with an energy-restricted Mediterranean diet and physical activity enhances HDL function: a substudy of the PREDIMED-Plus randomized controlled trial. American Journal of Clinical Nutrition, 2021, 114, 1666-1674.	2.2	15
659	APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups. Lipids in Health and Disease, 2021, 20, 113.	1.2	12
661	Rare, Damaging DNA Variants in CORIN and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses. Circulation Genomic and Precision Medicine, 2021, 14, e003399.	1.6	10
662	Small Dense Low-Density Lipoprotein Cholesterol: A Residual Risk for Rapid Progression of Non-Culprit Coronary Lesion in Patients with Acute Coronary Syndrome. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1161-1174.	0.9	22
663	Quantitative proteomics of plasma and liver reveals the mechanism of turmeric in preventing hyperlipidemia in mice. Food and Function, 2021, 12, 10484-10499.	2.1	8

#	Article	IF	Citations
664	Systematic analysis of binding of transcription factors to noncoding variants. Nature, 2021, 591, 147-151.	13.7	89
665	Choosing a genome editing strategy and target site. , 2021, , 21-39.		0
666	Exploration of Serum Marker Proteins in Mice Induced by Babesia microti Infection Using a Quantitative Proteomic Approach. Protein Journal, 2021, 40, 119-130.	0.7	2
667	Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 85-89.	1.2	3
668	Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy. Methods in Molecular Biology, 2020, 2176, 69-85.	0.4	10
669	Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames. Advances in Experimental Medicine and Biology, 2017, 983, 129-146.	0.8	15
670	Prospective Advances in Non-coding RNAs Investigation. Advances in Experimental Medicine and Biology, 2020, 1229, 385-426.	0.8	1
671	Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapiesâ€"a Clinical Perspective. Cardiovascular Drugs and Therapy, 2021, 35, 1269-1279.	1.3	13
672	Key differences between apoC-III regulation and expression in intestine and liver. Biochemical and Biophysical Research Communications, 2017, 491, 747-753.	1.0	10
673	Very Low-Density Lipoprotein Cholesterol May Mediate a Substantial Component of the Effect of Obesity on Myocardial Infarction Risk: The Copenhagen General Population Study. Clinical Chemistry, 2021, 67, 276-287.	1.5	16
674	Apolipoprotein genetic variants and hereditary amyloidosis. Current Opinion in Lipidology, 2021, 32, 132-140.	1.2	2
675	Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance. Current Opinion in Lipidology, 2021, 32, 103-111.	1.2	11
685	Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes. Journal of Clinical Investigation, 2019, 129, 4165-4179.	3.9	76
686	ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. Journal of Clinical Investigation, 2016, 126, 2855-2866.	3.9	186
687	Distinct but complementary contributions of PPAR isotypes to energy homeostasis. Journal of Clinical Investigation, 2017, 127, 1202-1214.	3.9	270
688	Apolipoprotein CIII and Angiopoietin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin. Journal of the Endocrine Society, 2021, 5, bvaa191.	0.1	6
689	APOC3 may not be a predictor of risk of ischemic vascular disease in the Chinese population. F1000Research, 0, 3, 270.	0.8	2
690	APOC3 may not be a predictor of risk of ischemic vascular disease in the Chinese population. F1000Research, 2014, 3, 270.	0.8	3

#	Article	IF	Citations
691	Analysis of Low Frequency Protein Truncating Stop-Codon Variants and Fasting Concentration of Growth Hormone. PLoS ONE, 2015, 10, e0128348.	1.1	4
692	Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. PLoS ONE, 2017, 12, e0182999.	1.1	5
693	Therapeutic plasma exchange for the management of severe gestational hypertriglyceridaemic pancreatitis due to lipoprotein lipase mutation. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	4
694	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review, 2020, 15, 1-9.	0.7	38
695	Diabetes in Population Isolates: Lessons from Greenland. Review of Diabetic Studies, 2015, 12, 320-329.	0.5	11
696	Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. Current Vascular Pharmacology, 2019, 17, 332-340.	0.8	6
697	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Current Vascular Pharmacology, 2019, 17, 498-514.	0.8	38
698	Triglyceride and cardiovascular risk: A critical appraisal. Indian Journal of Endocrinology and Metabolism, 2016, 20, 418.	0.2	29
699	Dyslipidaemia of diabetes and the intestine. World Journal of Diabetes, 2015, 6, 970.	1.3	15
700	Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease. World Journal of Cardiology, 2019, 11, 256-265.	0.5	5
701	The Lausanne Institutional Biobank: A new resource to catalyse research in personalised medicine and pharmaceutical sciences. Swiss Medical Weekly, 2014, 144, w14033.	0.8	14
702	Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes. Journal of Biomedical Research, 2019, 33, 1.	0.7	40
703	Primary genetic disorders affecting high density lipoprotein (HDL). Drugs in Context, 2018, 7, 1-11.	1.0	11
704	Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. Frontiers in Cardiovascular Medicine, 2021, 8, 768119.	1.1	24
705	TMT-Based Plasma Proteomics Reveals Dyslipidemia Among Lowlanders During Prolonged Stay at High Altitudes. Frontiers in Physiology, 2021, 12, 730601.	1.3	4
706	Human genetics and its impact on cardiovascular disease. Journal of Cardiology, 2022, 79, 233-239.	0.8	10
707	Apolipoproteins in vascular biology and atherosclerotic disease. Nature Reviews Cardiology, 2022, 19, 168-179.	6.1	88
708	Residual Cardiovascular Risk Factors in Dyslipidemia. , 0, , .		0

#	Article	IF	Citations
709	Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects. Journal of Proteomics, 2022, 251, 104398.	1.2	7
710	Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 295-308.	1.1	7
711	A Modern Approach to Dyslipidemia. Endocrine Reviews, 2022, 43, 611-653.	8.9	110
712	New Therapies for Lowering Triglyceride-Rich Lipoproteins. Journal of the American College of Cardiology, 2021, 78, 1817-1830.	1.2	28
713	Genetic Epidemiology of Atherosclerotic Vascular Disease. , 2014, , 1-24.		0
714	Obesity research: Status quo and future outlooks. World Journal of Translational Medicine, 2014, 3, 119.	3.5	0
715	MEASURES OF EXPOSURE IMPACT GENETIC ASSOCIATION STUDIES: AN EXAMPLE IN VITAMIN K LEVELS AND VKORC1. , 2014, , .		2
716	Apolipoprotein C-III's role in cardiovascular diseases, a short review. ScienceOpen Research, 2014, .	0.6	0
717	Personalized Management of Cardiovascular Disorders. , 2015, , 479-509.		1
718	Pancreatic Cancer Stem Cells. , 2015, , 247-271.		0
719	Genetic Epidemiology of Atherosclerotic Vascular Disease. , 2015, , 1517-1539.		0
721	Translational Research Methods: Basics of Renal Molecular Biology. , 2016, , 425-445.		0
722	Genomic Medicine and Ethnic Differences in Cardiovascular Disease Risk. , 2016, , 209-235.		0
723	Genetics of (Premature) Coronary Artery Disease. , 2016, , 355-371.		0
724	LDL-Related Intolerance to Glucose, Diastolic Hypertension and Additive Effects of Smoking Were Found with Three Female Study Groups. Health, 2016, 08, 230-250.	0.1	0
725	Genetics of Endocrinology. , 2016, , 49-68.		1
727	ASGR1 - a new target for lowering non-HDL cholesterol. Global Cardiology Science & Practice, 2016, 2016, e201614.	0.3	1
731	Loss-of-function of neuroplasticity-related genes confers risk for human neurodevelopmental disorders. , 2018, , .		6

#	Article	IF	Citations
733	Salt and Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 675-693.	0.1	0
738	Genetics of Coronary Disease. , 2019, , 21-36.		0
745	Hepatocyte Growth Factor and Macrophage-stimulating Protein â€œHingeâ€•Analogs to Treat Pancreatic Cancer. Current Cancer Drug Targets, 2019, 19, 782-795.	0.8	1
746	Lipid disorders. , 2020, , 2055-2097.		0
747	Drug Discovery for Coronary Artery Disease. Advances in Experimental Medicine and Biology, 2020, 1177, 297-339.	0.8	6
748	Genetics of (Premature) Coronary Artery Disease. , 2020, , 413-430.		0
751	Fine genetic mapping of the chromosome 11q23.3 region in a Han Chinese population: insights into the apolipoprotein genes underlying the blood lipid-lipoprotein variances. Journal of Genetics and Genomics, 2020, 47, 756-769.	1.7	0
752	Personalized Therapy of Cardiovascular Disorders. , 2021, , 279-316.		0
753	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. Contemporary Cardiology, 2021, , 139-158.	0.0	2
754	High-Density Lipoproteins. Contemporary Cardiology, 2021, , 341-361.	0.0	1
755	Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)₂Âand the larger HDL₃Âfrom very low-density lipoprotein (VLDL). Biological Chemistry, 2021, 402, 439-449.	1.2	6
756	Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins. Vestnik Medicinskogo Instituta REAVIZ ReabilitaciÃ¢, VraÄ•i Zdorovê¹e, 2020, , 88-104.	0.1	0
757	The prevention and treatment of bleeding associated with direct oral anticoagulants. Klinicheskaia Meditsina, 2020, 96, 491-497.	0.2	0
759	Genetics and regulation of HDL metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159060.	1.2	2
760	Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	1
761	The forkhead box O family in insulin action and lipid metabolism. , 2020, , 247-272.		0
763	Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects. Frontiers in Cardiovascular Medicine, 2021, 8, 760140.	1.1	14
764	Measures of exposure impact genetic association studies: an example in vitamin K levels and VKORC1. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2015, , 161-70.	0.7	2

#	Article	IF	Citations
765	A Comparative Overview of Prescription Omega-3 Fatty Acid Products. P and T, 2015, 40, 826-57.	1.0	23
766	Loss-of-function of neuroplasticity-related genes confers risk for human neurodevelopmental disorders. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2018, 23, 68-79.	0.7	6
768	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal, 2022, 43, 1401-1412.	1.0	78
769	New insights into the pathological development of dyslipidemia in patients with hypothyroidism. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	4
770	Recruiting a transcription factor in the liver to prevent atherosclerosis. Journal of Clinical Investigation, 2021, 131, .	3.9	3
771	Association of apolipoprotein Cs with new-onset type 2 diabetes mellitus: findings from the Chinese multi-provincial cohort study. BMJ Open, 2021, 11, e052388.	0.8	2
772	Effect of APOB polymorphism rs562338 (G/A) on serum proteome of coronary artery disease patients: a â€œproteogenomicâ€•approach. Scientific Reports, 2021, 11, 22766.	1.6	3
773	Apolipoprotein Câ€‖I predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria. Journal of Internal Medicine, 2022, 291, 338-349.	2.7	10
774	The genetic basis of sudden death in young people â€“ Cardiac and non-cardiac. Gene, 2022, 810, 146067.	1.0	3
775	Bayesian model comparison for rare-variant association studies. American Journal of Human Genetics, 2021, 108, 2354-2367.	2.6	2
776	Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 4912-4922.	1.3	6
777	Novel therapeutic targets and agents for pediatric dyslipidemia. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110583.	1.4	4
778	Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Endocrine Connections, 2022, 11, .	0.8	20
779	Adipocyte-specific tribbles pseudokinase 1 regulates plasma adiponectin and plasma lipids in mice. Molecular Metabolism, 2022, 56, 101412.	3.0	4
780	High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?. Handbook of Experimental Pharmacology, 2021, , 157-200.	0.9	3
781	Addressing dyslipidemic risk beyond LDL-cholesterol. Journal of Clinical Investigation, 2022, 132, .	3.9	51
783	Rare coding variants in 35 genes associate with circulating lipid levelsâ€”A multi-ancestry analysis of 170,000 exomes. American Journal of Human Genetics, 2022, 109, 81-96.	2.6	24
784	Hyperlipidemia and hypothyroidism. Clinica Chimica Acta, 2022, 527, 61-70.	0.5	35

#	Article	IF	Citations
785	Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins. Current Atherosclerosis Reports, 2022, 24, 1-12.	2.0	4
786	Single-Cell Sequencing of Hepatocellular Carcinoma Reveals Cell Interactions and Cell Heterogeneity in the Microenvironment. International Journal of General Medicine, 2021, Volume 14, 10141-10153.	0.8	6
787	CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. Metabolites, 2021, 11, 857.	1.3	8
788	Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions. Methods in Molecular Biology, 2022, 2419, 3-19.	0.4	9
789	Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function APOC3 variants in non-Europeans. American Heart Journal Plus, 2022, 13, 100128.	0.3	1
790	Genetically Engineered Hamster Models of Dyslipidemia and. Methods in Molecular Biology, 2022, 2419, 433-459.	0.4	1
791	Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nature Reviews Drug Discovery, 2022, 21, 417-439.	21.5	24
792	Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia. Science Advances, 2022, 8, eabm1418.	4.7	46
793	Treating Cardiovascular Disease with Liver Genome Engineering. Current Atherosclerosis Reports, 2022, 24, 75-84.	2.0	0
794	Sodium and Health: Old Myths and a Controversy Based on Denial. Current Nutrition Reports, 2022, 11, 172-184.	2.1	32
795	Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank. Nature Genetics, 2022, 54, 240-250.	9.4	68
796	BMP gradient along the intestinal villus axis controls zonated enterocyte and goblet cell states. Cell Reports, 2022, 38, 110438.	2.9	45
797	A Novel Gene CDC27 Causes SLE and Is Associated With the Disease Activity. Frontiers in Immunology, 2022, 13, 876963.	2.2	5
798	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nature Reviews Cardiology, 2022, 19, 577-592.	6.1	59
799	A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?. BioDrugs, 2022, 36, 121-135.	2.2	9
800	Triglycerides. Medical Clinics of North America, 2022, 106, 299-312.	1.1	2
801	Targeting triglycerides to lower residual cardiovascular risk. Expert Review of Cardiovascular Therapy, 2022, , 1-7.	0.6	2
802	TMEM43 promotes pancreatic cancer progression by stabilizing PRPF3 and regulating RAP2B/ERK axis. Cellular and Molecular Biology Letters, 2022, 27, 24.	2.7	14

#	Article	IF	Citations
803	An Amish founder population reveals rare-population genetic determinants of the human lipidome. Communications Biology, 2022, 5, 334.	2.0	7
804	Potential biomarkers identified by tandem mass tags based quantitative proteomics for diagnosis and classification of Guillainâ€“BarrÃ© syndrome. European Journal of Neurology, 2022, 29, 1155-1164.	1.7	4
805	CRISPR/Cas9-mediated knockout of APOC3 stabilizes plasma lipids and inhibits atherosclerosis in rabbits. Lipids in Health and Disease, 2021, 20, 180.	1.2	14
806	Gene editing and its applications in biomedicine. Science China Life Sciences, 2022, 65, 660-700.	2.3	20
807	Approach to patients with hypertriglyceridemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2023, 37, 101659.	2.2	2
810	The British Cardiovascular Society and clinical studies in ischaemic heart disease: from RITA to ORBITA, and beyond. Heart, 2022, 108, 800-806.	1.2	0
811	RNA-based therapy in the management of lipid disorders: a review. Lipids in Health and Disease, 2022, 21, 41.	1.2	9
813	Plasma apoCIII Levels in Relation to Inflammatory Traits and Metabolic Syndrome in Patients not Treated with Lipid-lowering Drugs Undergoing Coronary Angiography. Biomedical and Environmental Sciences, 2017, 30, 1-9.	0.2	1
814	Blood lipids and molecular pathways of atherogenesis. , 2022, , 623-637.		0
815	Ancient Diatom DNA. , 2022, , 87-108.		1
816	Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis. Frontiers in Cardiovascular Medicine, 2022, 9, 889743.	1.1	1
817	HDL, heart disease, and the lung. Journal of Lipid Research, 2022, 63, 100217.	2.0	1
818	Impact of small dense low-density lipoprotein cholesterol on cholesterol crystals in patients with acute coronary syndrome: An optical coherence tomography study. Journal of Clinical Lipidology, 2022, , .	0.6	7
819	HDL and ASCVD. Advances in Experimental Medicine and Biology, 2022, 1377, 109-118.	0.8	0
820	Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 2022, 13, e00500.	1.3	4
821	Dyslipidemia and coronary artery calcium: From association to development of a risk-prediction nomogram. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1944-1954.	1.1	5
822	Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis. Frontiers in Molecular Biosciences, 2022, 9, .	1.6	16
823	A comparative evaluation of cardiac and neurological safety status of two commonly used oral hypoglycaemic agents in T2-DM Swiss albino mice model. Metabolism Open, 2022, 14, 100191.	1.4	1

#	Article	IF	Citations
824	Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?. Journal of Clinical Medicine, 2022, 11, 3331.	1.0	2
825	The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity. Advanced Biology, 2022, 6, .	1.4	13
826	Lipoprotein profiles associated with exposure to poly- and perfluoroalkyl substances (PFASs) in the EuroMix human biomonitoring study. Environmental Pollution, 2022, 308, 119664.	3.7	9
827	RNA therapies for cardiovascular disease. , 2022, , 413-425.		0
828	Safety and efficacy of therapies for chylomicronemia. Expert Review of Clinical Pharmacology, 2022, 15, 395-405.	1.3	15
829	Volanesorsen to treat severe hypertriglyceridaemia: AÂpooled analysis of randomized controlled trials. European Journal of Clinical Investigation, 2022, 52, .	1.7	15
830	New and Emerging Therapies for Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, , .	1.2	3
831	Lipoprotein Assessment in the twenty-first Century. Endocrinology and Metabolism Clinics of North America, 2022, 51, 459-481.	1.2	3
832	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. Journal of Clinical Medicine, 2022, 11, 3884.	1.0	22
833	Hypertriglyceridemia. Endocrinology and Metabolism Clinics of North America, 2022, 51, 539-555.	1.2	9
834	Dyslipidemia in Diabetes. Endocrinology and Metabolism Clinics of North America, 2022, 51, 603-624.	1.2	13
835	Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk. Current Cardiovascular Risk Reports, 0, , .	0.8	0
837	New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes and Metabolism Journal, 2022, 46, 517-532.	1.8	23
838	Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention. Current Atherosclerosis Reports, 2022, 24, 767-778.	2.0	7
839	Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction. Journal of Clinical Lipidology, 2022, 16, 725-732.	0.6	3
840	The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Frontiers in Genetics, 0, 13, .	1.1	16
841	Inframe insertion and splice site variants in MFGE8 associate with protection against coronary atherosclerosis. Communications Biology, 2022, 5, .	2.0	9
842	The association of remnant cholesterol (RC) and interaction between RC and diabetes on the subsequent risk of hypertension. Frontiers in Endocrinology, 0, 13, .	1.5	5

#	Article	IF	Citations
844	Whole Exome Sequencing Revealed Variants That Predict Pulmonary Artery Involvement in Patients with Takayasu Arteritis. Journal of Inflammation Research, 0, Volume 15, 4817-4831.	1.6	3
845	Association of lipid metabolism-related gene promoter methylation with risk of coronary artery disease. Molecular Biology Reports, 2022, 49, 9373-9378.	1.0	2
846	Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia. Molecular Therapy - Nucleic Acids, 2022, 29, 551-562.	2.3	8
847	Lipoprotein sialylation in atherosclerosis: Lessons from mice. Frontiers in Endocrinology, 0, 13, .	1.5	3
848	A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy. Journal of Lipid and Atherosclerosis, 2022, 11, 250.	1.1	1
849	Precision Medicine in Cardiovascular Disease Practice. , 2022, , 53-66.		0
850	Obesity, Triglycerides, Remnant Cholesterol, and Other Causal Factors in Aortic Valve Stenosis: A Review. Cardiometabolic Syndrome Journal, 2022, 2, 108.	1.0	1
851	Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations. JCI Insight, 2022, 7, .	2.3	11
852	Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII. BioFactors, 2023, 49, 153-172.	2.6	1
853	Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia. Endocrinology and Metabolism, 2022, 37, 575-586.	1.3	13
854	Relationship between the development of hyperlipidemia in hypothyroidism patients. Molecular Biology Reports, 0, , .	1.0	0
855	A single-day mouse mesenteric lymph surgery in mice: an updated approach to study dietary lipid absorption, chylomicron secretion, and lymphocyte dynamics. Journal of Lipid Research, 2022, 63, 100284.	2.0	0
856	Management of Resectable and Borderline Resectable Disease: Radiation Oncology. , 2022, , 153-171.		0
857	A copula-based set-variant association test for bivariate continuous, binary or mixed phenotypes. International Journal of Biostatistics, 2022, .	0.4	0
858	Cardiovascular Diseases and their Novel Therapeutic Interventions: A Literature Review. , 2022, 6, 1-9.		0
859	Gene Sequencing Identifies Perturbation in Nitric Oxide Signaling as a Nonlipid Molecular Subtype of Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2022, 15, .	1.6	4
860	Icosapent Ethyl for the Prevention of Cardiovascular Events. EMJ Cardiology, 0, , 56-65.	0.0	0
861	Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review. Journal of Clinical Medicine, 2022, 11, 6773.	1.0	7

#	Article	IF	Citations
862	Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
864	Whole-exome sequence analysis of anthropometric traits illustrates challenges in identifying effects of rare genetic variants. Human Genetics and Genomics Advances, 2023, 4, 100163.	1.0	2
866	Genetic analysis of DNA methylation in dyslipidemia: a case-control study. PeerJ, 0, 10, e14590.	0.9	1
868	Gene editing for dyslipidemias: New tools to â€œcutâ€•lipids. Atherosclerosis, 2023, 368, 14-24.	0.4	5
870	Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 388-398.	1.1	26
871	Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current Atherosclerosis Reports, 2023, 25, 1-17.	2.0	28
872	Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing statin treatment. Journal of Clinical Lipidology, 2023, 17, 281-290.	0.6	1
873	APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism. Current Atherosclerosis Reports, 2023, 25, 67-76.	2.0	9
874	PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. International Journal of Molecular Sciences, 2023, 24, 2319.	1.8	7
875	Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemiaâ€”The Future Is Here. Pharmaceutics, 2023, 15, 459.	2.0	4
876	Silencing ApoC3 alleviates LPS-induced acute lung injury by inhibiting TLR signaling pathway. Immunologic Research, 2023, 71, 687-697.	1.3	1
877	Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies. Journal of the American College of Cardiology, 2023, 81, 1646-1658.	1.2	7
878	What is really new in triglyceride guidelines?. Current Opinion in Endocrinology, Diabetes and Obesity, 2023, 30, 73-80.	1.2	0
879	Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease. JAMA Cardiology, 2023, 8, 258.	3.0	10
880	Remnant cholesterol is independently associated with diabetes, even if the traditional lipid is at the appropriate level: A report from the <scp>REACTION</scp> study. Journal of Diabetes, 2023, 15, 204-214.	0.8	2
881	Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. Journal of Clinical Medicine, 2023, 12, 1382.	1.0	2
882	Apolipoprotein C3 induces inflammasome activation only in its delipidated form. Nature Immunology, 2023, 24, 408-411.	7.0	8
884	Apolipoprotein C3 is negatively associated with estrogen and mediates the protective effect of estrogen on hypertriglyceridemia in obese adults. Lipids in Health and Disease, 2023, 22, .	1.2	1

#	Article	IF	Citations
886	Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits. ELife, 0, 12, .	2.8	0
887	Tocilizumabâ€related hypertriglyceridemia is independent of key molecules regulating lipid metabolism. European Journal of Clinical Investigation, 0, , .	1.7	1
888	Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nature Reviews Cardiology, 2023, 20, 600-616.	6.1	22
889	Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment. , 2024, , 32-41.e2.		0
890	Special Patient Populations. , 2024, , 336-344.e2.		1
891	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
893	Diabetes and Dyslipidemia. Contemporary Cardiology, 2023, , 425-472.	0.0	3
897	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. Contemporary Diabetes, 2023, , 821-878.	0.0	0
898	Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes. Contemporary Diabetes, 2023, , 169-194.	0.0	0
901	Evolving Therapeutic Targets. , 2024, , 268-274.e1.		0
902	Special Patient Populations. , 2024, , 287-297.e2.		0
922	Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia. Current Atherosclerosis Reports, 2023, 25, 1101-1111.	2.0	3
923	How to Handle Elevated Triglycerides: Life after PROMINENT. Current Atherosclerosis Reports, 2023, 25, 921-929.	2.0	1
925	Atherosclerosis is the outcome of adaptive complexity in the Arterial Endothelial Microenvironment. , 2024, , 259-277.		0